Genor Biopharma Holdings Limited (HK:6998)
:6998
Want to see HK:6998 full AI Analyst Report?
Total Valuation
Genor Biopharma Holdings Limited has a market cap or net worth of HK$5.92B. The enterprise value is HK$1.78B.
Market CapHK$5.92B
Enterprise ValueHK$1.78B
Share Statistics
Genor Biopharma Holdings Limited has 2,011,213,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,011,213,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Genor Biopharma Holdings Limited’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.09%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)9.09%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee100.96M
Profits Per Employee20.68M
Employee Count24
Asset Turnover0.37
Inventory Turnover2.50
Valuation Ratios
The current PE Ratio of Genor Biopharma Holdings Limited is 2.0. Genor Biopharma Holdings Limited’s PEG ratio is -0.04.
PE Ratio2.0
PS Ratio1.86
PB Ratio1.17
Price to Fair Value1.17
Price to FCF11.17
Price to Operating Cash Flow13.17
PEG Ratio-0.04
Income Statement
In the last 12 months, Genor Biopharma Holdings Limited had revenue of 2.42B and earned 388.93M in profits. Earnings per share was 0.23.
Revenue2.42B
Gross Profit1.34B
Operating Income619.27M
Pretax Income483.42M
Net Income388.93M
EBITDA929.10M
Earnings Per Share (EPS)0.23
Cash Flow
In the last 12 months, operating cash flow was 258.34M and capital expenditures -45.91M, giving a free cash flow of 212.42M billion.
Operating Cash Flow258.34M
Free Cash Flow212.42M
Free Cash Flow per Share0.11
Dividends & Yields
Genor Biopharma Holdings Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.40
52-Week Price Change37.85%
50-Day Moving Average2.80
200-Day Moving Average3.23
Relative Strength Index (RSI)71.48
Average Volume (3m)909.38K
Important Dates
Genor Biopharma Holdings Limited upcoming earnings date is Sep 2, 2026, TBA (Confirmed).
Last Earnings DateMar 27, 2026
Next Earnings DateSep 2, 2026
Ex-Dividend Date―
Financial Position
Genor Biopharma Holdings Limited as a current ratio of 1.00, with Debt / Equity ratio of 38.57%
Current Ratio1.00
Quick Ratio0.80
Debt to Market Cap0.32
Net Debt to EBITDA0.46
Interest Coverage Ratio4.59
Taxes
In the past 12 months, Genor Biopharma Holdings Limited has paid 94.49M in taxes.
Income Tax94.49M
Effective Tax Rate0.20
Enterprise Valuation
Genor Biopharma Holdings Limited EV to EBITDA ratio is 5.32, with an EV/FCF ratio of 12.23.
EV to Sales2.04
EV to EBITDA5.32
EV to Free Cash Flow12.23
EV to Operating Cash Flow10.94
Balance Sheet
Genor Biopharma Holdings Limited has HK$1.06B in cash and marketable securities with HK$1.49B in debt, giving a net cash position of -HK$431.36M billion.
Cash & Marketable SecuritiesHK$1.06B
Total DebtHK$1.49B
Net Cash-HK$431.36M
Net Cash Per Share-HK$0.21
Tangible Book Value Per ShareHK$0.13
Margins
Gross margin is 55.55%, with operating margin of 25.56%, and net profit margin of 16.05%.
Gross Margin55.55%
Operating Margin25.56%
Pretax Margin19.95%
Net Profit Margin16.05%
EBITDA Margin38.34%
EBIT Margin25.56%
Analyst Forecast
The average price target for Genor Biopharma Holdings Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1117.02%
EPS Growth Forecast―